| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6779468 | ROCKWELL MEDICAL INC | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
Dec, 2016
(7 years ago) | |
| US6689275 | ROCKWELL MEDICAL INC | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
Dec, 2016
(7 years ago) | |
| US7857977 | ROCKWELL MEDICAL INC | Packaging of ferric pyrophosphate for dialysis |
Sep, 2027
(3 years from now) | |
| US7816404 | ROCKWELL MEDICAL INC | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
Apr, 2029
(4 years from now) | |
Triferic is owned by Rockwell Medical Inc.
Triferic contains Ferric Pyrophosphate Citrate.
Triferic has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Triferic are:
- US6779468
- US6689275
Triferic was authorised for market use on 23 January, 2015.
Triferic is available in powder;intravenous, solution;intravenous dosage forms.
Triferic can be used as method of iron administration to treat patients in need of iron replacement.
The generics of Triferic are possible to be released after 17 April, 2029.
Drugs and Companies using FERRIC PYROPHOSPHATE CITRATE ingredient
Market Authorisation Date: 23 January, 2015
Treatment: Method of iron administration to treat patients in need of iron replacement
Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS
TRIFERIC family patents
